Clinical Trial Update: Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial compares dabigatran to oral anti-Xa inhibitors in Staphylococcus aureus bacteremia-related conditions and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Bacteremia
• Staphylococcus Aureus Endocarditis
• Staphylococcus Aureus Septicemia

Drugs mentioned

• Dabigatran (Dabigatran etexilate)
• Oral anti-Xa inhibitors

Snippet

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre | Conditions: Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia | Phase 4 | Status: RECRUITING